Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2024]

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses...

Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia

$Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma ( Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia )$

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA

MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )

Zamtocabtagene autoleucel improves event-free survival vs standard of care in...

Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL ( Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany )

Anitocabtagene autoleucel achieves deep and durable responses in relapsed...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

$Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )$

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA

Exploring genomic insights in acute lymphoblastic leukaemia treatment ( Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights...

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Racial disparities in AML: Black patients show inferior survival despite...

Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine...

Racial disparities in AML: Black patients show inferior survival despite similar cytogenetics and treatment response ( Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA )

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Asciminib shows high molecular response, favourable safety in 2L CML-CP ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

More from ecancer